EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Prevalence, patient characteristics, and outcomes of high-dose upadacitinib in inflammatory bowel disease

Julian Azar iD, Rofina Johnkennedy, Louis J Levine, Ibrahim AlOmar, Abdulelah AlMutairdi, Mashary Attamimi, Deborah D Proctor, Jill K J Gaidos, Badr Al-Bawardy iD

Therapeutic Advances in Gastroenterology · 2026-05 · 19

DOI: 10.1177/17562848261451333 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Gastroenterology, online erschienen am 21.05.2026. Verfasst von Julian Azar und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Off-label high-dose upadacitinib (UPA) may be necessary for select inflammatory bowel disease (IBD) patients.

Objectives

To evaluate the rates, patient characteristics, and outcomes of extended induction and high-dose UPA maintenance in IBD.

Design

We conducted a two-center, retrospective cohort study of IBD patients treated with UPA from January 1, 2022, to March 1, 2025.

Methods

Extended induction was defined as receiving UPA 45 mg for 16 weeks in ulcerative colitis (UC) and 24 weeks in Crohn’s disease (CD). High-dose maintenance was defined as continuing UPA 45 mg after induction/extended induction. Primary outcomes included rates and characteristics of high-dose maintenance. Secondary outcomes included clinical response (CR), steroid-free clinical remission (SFCR), endoscopic remission (ER), and adverse events, comparing standard and high-dose UPA groups.

Results

Among 128 patients (46.9% CD, 48.4% UC, 4.7% IBD-unclassified), 51.6% ( n = 66) received extended induction and 34.4% ( n = 44) continued high-dose UPA maintenance. On multivariate analysis, UPA high-dose maintenance patients were more likely to have a higher number of prior biologic exposures (odds ratio (OR) 1.84, 95% confidence interval (CI) 1.05–3.19, p = 0.022) and concomitant biologic use (OR 6.18, 95% CI 1.15–33.18, p = 0.034). In the high-dose maintenance group, rates of CR were 73.7%, SFCR 65.8%, and ER 36.7%. Adverse event rates were similar between high- and standard-dose maintenance groups (25% vs 26.8%), with no cases of herpes zoster, venous thromboembolism, or major adverse cardiovascular events.

Conclusion

One-third of patients remained on high-dose UPA maintenance, reflecting more refractory disease and modest response rates. Treatment was generally well tolerated. Larger, long-term studies are needed to validate safety.

Schlagwörter

Stichwörter der Autor:innen

Crohn’s diseaseinflammatory bowel diseaseulcerative colitisupadacitinib

Autor:innen und Institutionen

  • Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
  • Department of Internal Medicine, Yale New Haven Hospital, Bridgeport, CT, USA.
  • Section of Digestive Diseases, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, King Faisal Specialist Hospital, Riyadh, Saudi Arabia.
  • College of Medicine, Alfaisal University, Riyadh, Saudi Arabia.
  • Division of Gastroenterology and Hepatology, Department of Internal Medicine, King Faisal Specialist Hospital and Research Center, P.O. Box 3354, Riyadh 11121, Saudi Arabia.

ORCID-Profile: Julian Azar, Badr Al-Bawardy

Zitieren

APA

Azar, J., Johnkennedy, R., Levine, L. J., AlOmar, I., AlMutairdi, A., Attamimi, M., Proctor, D. D., Gaidos, J. K. J., & Al-Bawardy, B. (2026). Prevalence, patient characteristics, and outcomes of high-dose upadacitinib in inflammatory bowel disease. Therapeutic Advances in Gastroenterology, 19. https://doi.org/10.1177/17562848261451333

Vancouver

Azar J, Johnkennedy R, Levine LJ, AlOmar I, AlMutairdi A, Attamimi M, et al. Prevalence, patient characteristics, and outcomes of high-dose upadacitinib in inflammatory bowel disease. Therapeutic Advances in Gastroenterology. 2026;19. doi:10.1177/17562848261451333

BibTeX
@article{Azar2026,
  author = {Azar, Julian and Johnkennedy, Rofina and Levine, Louis J and AlOmar, Ibrahim and AlMutairdi, Abdulelah and Attamimi, Mashary and Proctor, Deborah D and Gaidos, Jill K J and Al-Bawardy, Badr},
  title = {Prevalence, patient characteristics, and outcomes of high-dose upadacitinib in inflammatory bowel disease},
  journal = {Therapeutic Advances in Gastroenterology},
  year = {2026},
  volume = {19},
  doi = {10.1177/17562848261451333}
}
Kostenlos starten →